Procter & Gamble Health LimitedPGHLCorporate

Pharmaceuticals - Multinational Latest results: Jun 2026 14 quarters of data

₹5,200.00

MCap ₹8,632 Cr · P/E 24.1

Procter & Gamble Health Limited — Stock analysis & AI research Procter & Gamble Health Limited — Seasonality — best & worst months Procter & Gamble Health Limited — Technical indicators & charts Procter & Gamble Health Limited — Technical setup — score, trend, support & resistance Procter & Gamble Health Limited — Falling Wedge pattern forming Procter & Gamble Health Limited — Live exchange announcements

📋 High ROE Stocks 📋 High ROCE Stocks 📋 High Operating Margin Stocks 📋 Low Debt Stocks 📋 Quality Stocks 📋 Quality Stocks Near 52-Week Low 📈 Death Cross Stocks 📈 MACD Bullish Crossover 📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹364 Cr

Sales · Jun 2026

+7.3% YoY

₹100 Cr

Operating Profit · Jun 2026

+10.7% YoY

27.4%

OPM % · Jun 2026

+3.4% YoY

₹96 Cr

Net Profit · Jun 2026

+45.7% YoY

₹57.92

EPS · Jun 2026

+45.3% YoY

📝 Procter & Gamble Health Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Procter & Gamble Health Limited reported revenue of ₹364 crore for the quarter ended June 2026 (Q1 FY27), up 7.3% from ₹339 crore in the same quarter last year, and down 1.7% sequentially over the March 2026 quarter.

Net profit rose 45.7% year-on-year to ₹96 crore, from ₹66 crore. Earnings per share (EPS) came in at ₹57.92.

Operating profit stood at ₹100 crore — an operating margin (OPM) of 27.4%, compared with 26.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Procter & Gamble Health Limited posted revenue of ₹1,408 crore, a growth of 15.6% over FY25, with a net profit of ₹328 crore (up 30.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,433 crore with a net profit of ₹358 crore.

Valuation snapshot

At the current price of ₹5,200.00, PGHL has a market capitalisation of ₹8,632 crore and a trailing P/E of about 24.1.

Within the Pharmaceuticals - Multinational industry, it is the largest of the 3 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.82%, foreign institutional investors (FIIs) 6.42%, domestic institutional investors (DIIs) 12.63%, public shareholders 29.13% of Procter & Gamble Health Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹8,632 Cr

Current Price ?

₹5,200.0

P/E ?

24.10above ind

Industry P/E ?

24.10

P/B ?

16.44

P/S ?

6.02

P/FCF ?

26.72

Enterprise Value ?

₹8,641 Cr

EV/EBITDA ?

18.56

PEG ?

1.27

Earnings Yield ?

5.1%

Dividend Yield ?

2.40%

Profitability & Returns

Sales (TTM) ?

₹1,433 Cr

OPM ?

32.5%

Profit after tax (TTM) ?

₹358 Cr

EPS (TTM) ?

₹215.76

ROCE ?

84.0%

ROE ?

68.2%

ROA ?

42.6%

Growth

Sales — latest qtr ?

₹364 Cr

PAT — latest qtr ?

₹96 Cr

YoY qtr sales growth ?

7.3%

YoY qtr profit growth ?

45.7%

Sales growth (3y) ?

Sales growth (5y) ?

Profit growth (3y) ?

19%

Profit growth (5y) ?

Financial Health

Debt ?

₹9 Cr

Debt to Equity ?

0.02

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

51.82%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-23.5%

Return 6 months ?

3.5%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	321	301	305	310	252	284	313	310	311	339	325	374	370	364	+7.3%	-1.7%
Operating Profit	80	45	89	102	67	48	114	123	81	90	120	110	136	100	+10.7%	-26.8%
Other Income	5	5	6	5	2	2	3	4	3	4	5	4	4	4	-3.0%	-3.0%
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	—	—
Depreciation	6	6	6	7	7	7	6	6	5	5	6	6	6	6	+20.4%	+0.3%
Profit Before Tax	79	44	88	100	63	23	111	122	79	89	119	109	133	129	+45.1%	-2.9%
Net Profit	59	30	66	72	47	17	82	91	61	66	89	78	95	96	+45.7%	+1.2%
EPS	35.66	17.96	39.50	43.42	28.05	10.11	49.60	54.76	36.86	39.87	53.34	46.74	56.99	57.92	+45.3%	+1.6%
OPM %	24.9%	15.0%	29.2%	32.9%	26.6%	17.0%	36.4%	39.7%	26.0%	26.5%	36.9%	29.4%	36.8%	27.4%	+3.4%	-25.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹1,218 Cr	₹1,408 Cr	₹1,433 Cr	+15.6%
Operating Profit	₹366 Cr	₹456 Cr	₹466 Cr	+24.5%
OPM %	30.07%	32.39%	32.50%	+7.7%
NPM %	20.59%	23.30%	25.00%	+13.2%
Other Income	₹12 Cr	₹17 Cr	₹17 Cr	+40.1%
Depreciation	₹24 Cr	₹23 Cr	₹24 Cr	-4.8%
Interest	₹0 Cr	₹0 Cr	₹0 Cr	-100.0%
EBIT	₹342 Cr	₹433 Cr	₹442 Cr	+26.6%
PBT	₹335 Cr	₹450 Cr	₹490 Cr	+34.4%
Tax	₹6 Cr	—	₹33 Cr	—
Net Profit	₹251 Cr	₹328 Cr	₹358 Cr	+30.8%
EPS	₹151.33	₹196.94	₹214.99	+30.1%
Material Cost	₹86 Cr	—	₹105 Cr	—
Employee Cost	₹49 Cr	—	₹60 Cr	—
Extraordinary Items	₹-20 Cr	—	₹32 Cr	—

🏛️ Balance Sheet (latest 4 periods)

Metric	Jun 2023	Jun 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	17	17	17	17	+0.0%
Reserves	734	522	520	508	-2.3%
Borrowings	12	10	8	9	+12.5%
Other Liabilities	338	247	250	308	+23.2%
Total Liabilities	1,101	794	794	841	+5.9%
Fixed Assets	144	128	116	102	-12.1%
CWIP	32	6	11	14	+27.3%
Investments	0	0	0	0	—
Other Assets	925	660	667	726	+8.8%
Total Assets	1,101	794	794	841	+5.9%

💧 Cash Flow (latest 4 periods)

Metric	Jun 2023	Jun 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	236	228	169	338	+100.0%
Cash from Investing Activity	-22	-7	10	1	-90.0%
Cash from Financing Activity	-98	-418	-235	-344	-46.4%
Net Cash Flow	116	-197	-56	-5	+91.1%
Free Cash Flow	198	207	168	323	+92.3%
CFO/OP	100%	102%	78%	97%	+24.4%

➗ Ratios (latest 4 periods)

Metric	Jun 2023	Jun 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	34	27	57	43	-24.6%
Inventory Days	136	120	152	137	-9.9%
Days Payable	239	184	239	192	-19.7%
Cash Conversion Cycle	-69	-37	-30	-13	+56.7%
Working Capital Days	15	19	48	30	-37.5%
ROCE %	45%	45%	48%	84%	+75.0%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	51.82%	51.82%	51.82%	51.82%	51.82%	51.82%	+0.0%
FIIs	6.99%	7.24%	6.97%	6.20%	6.33%	6.42%	+1.4%
DIIs	14.15%	13.90%	13.84%	13.67%	12.44%	12.63%	+1.5%
Public	27.03%	27.05%	27.37%	28.30%	29.42%	29.13%	-1.0%
No. of Shareholders	52,478	50,006	49,302	50,883	49,056	50,426	+2.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Multinational · 3 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	PGHL Procter & Gamble	₹5,321.00	8,833	24.7	1,433	358	32.5%	25.0%	15.6%	30.8%	7.3%	45.7%
2	SANOFICONR Sanofi Consumer	₹3,650.00	8,418	31.6	950	266	37.2%	28.0%	—	—	6.7%	12.8%
3	SANOFI Sanofi India	₹2,928.60	6,745	20.8	1,805	324	26.7%	18.0%	16.4%	1.8%	7.8%	19.3%

❓ Frequently asked questions

What was Procter & Gamble Health Limited's revenue in Q1 FY27?

What was Procter & Gamble Health Limited's net profit in Q1 FY27?